# Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD

Study · id `cardio:ct-nct04040959` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04040959](<https://clinicaltrials.gov/study/NCT04040959>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04040959

Browse, organ or system: Blood vessels; Kidneys  
Browse, condition area: High blood pressure; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 118 participants.

## Technical summary

Registry record NCT04040959. Randomized; quadruple masking; primary purpose treatment. Start 2019-11-19 (actual); primary completion 2026-07-20 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 118 participants (planned count; ClinicalTrials.gov record NCT04040959, source copy `cardio:ctgov-nct04040959-2026-10-02`, retrieved 2026-10-26)
- Started: 2019-11-19 (actual) (ClinicalTrials.gov record NCT04040959, source copy `cardio:ctgov-nct04040959-2026-10-02`, retrieved 2026-10-26)
- Primary completion: 2026-07-20 (actual) (ClinicalTrials.gov record NCT04040959, source copy `cardio:ctgov-nct04040959-2026-10-02`, retrieved 2026-10-26)
- Completion: 2027-07-20 (anticipated) (ClinicalTrials.gov record NCT04040959, source copy `cardio:ctgov-nct04040959-2026-10-02`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT04040959, source copy `cardio:ctgov-nct04040959-2026-10-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04040959-2026-10-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD
- Condition: Vascular Diseases
- Condition: Kidney Disease
- Condition: Blood Pressure
- Condition: Oxidative Stress
- Intervention (Drug): Nicotinamide riboside
- Lead sponsor: University of Colorado, Denver
- Lead sponsor class: OTHER
- Collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: University of Colorado, Denver (`cardio:org-university-of-colorado-denver`)
- Registry lists this organization as a collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (`cardio:niddk`)

## Provenance

Content hash: fc08e2b963fb1d460c7064f86a849963d88fc92b13cbb8d9fcab82ff3366f3aa
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
